RenalSense announced today that it raised $14 million to increase global commercialization efforts and advance its next-generation products.
Jerusalem-based RenalSense develops the FDA-cleared and CE-marked Clarity RMS critical care monitoring system for the early detection of changes in renal function and acute kidney injury (AKI) risk, along with treatment monitoring.
Clarity RMS has been installed across general and cardiovascular operating rooms and ICUs, as well as transplant and COVID-19 units. Future generation sensor-based products will seek to build upon Clarity RMS to provide additional diagnostic data about renal function, as well as other vital organ function, with eyes on implementation beyond the critical care setting.
Funding came in the form of a Series A round, led by BlueRed Partners Fund (Singapore), with contributions from large healthcare-focused family offices as well as existing shareholders, according to a news release.